APIE Therapeutics is developing orally delivered drug candidates that activate resident stem cells to enhance the repair and regeneration of vascular tissue damaged by chronic diseases. This approach addresses the inadequate wound-healing processes that lead to debilitating fibrosis and poor health outcomes for patients.
Funding
$25K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic diseases often lead to vascular tissue damage and inadequate wound-healing, resulting in debilitating fibrosis and poor patient outcomes. Current treatments do not effectively stimulate the body's natural repair mechanisms to regenerate damaged vascular tissue.
Solution
APIE Therapeutics is developing orally administered drug candidates designed to activate resident stem cells and enhance the repair and regeneration of vascular tissue damaged by chronic diseases. These drug candidates leverage Apelin Receptor Agonists to trigger resident stem cells, promoting their propagation and differentiation into appropriate cell types to repair damaged tissue. By turbocharging the body’s natural repair process, APIE's therapeutics aim to improve patient health outcomes in diseases driven by impaired wound-healing. The company's approach seeks to address the underlying causes of vascular damage and promote tissue regeneration.
Target Audience
The primary target audience includes patients suffering from chronic diseases with vascular tissue damage and impaired wound-healing, as well as healthcare providers seeking novel therapeutic options.
Features
- Orally delivered drug candidates for convenient administration
- Apelin Receptor Agonist technology to stimulate resident stem cells
- Targeted approach to enhance vascular tissue repair and regeneration
- Designed to address chronic diseases with vascular damage
- Aims to improve wound-healing processes and reduce fibrosis